In vitro and in vivo growth inhibition and G1 arrest in human cancer cell lines by diaminophenyladamantane derivatives

Anti-Cancer Drugs

Volumn 15, Issue 7, 2004, Pages 697-705

  Wang, Jane Jen ^a   Chen, Yu Chen ^b   Chi, Chin Wen ^b,c   Huang, Kuo Tong ^d   Chern, Yaw Terng ^e  

^a NATIONAL TAIPEI UNIVERSITY OF NURSING AND HEALTH SCIENCES   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Adamantane; Anticancer activity; G1 arrest

Indexed keywords

1,3 BIS(4 AMINOPHENYL)ADAMANTANE; 1,3 BIS[4 (4 AMINO 2 TRIFLUOROMETHYLPHENOXY)PHENYL]ADAMANTANE; 1,3 BIS[4 (4 AMINO 3 HYDROXYPHENOXY)PHENYL]ADAMANTANE; 1,3 BIS[4 (4 AMINOPHENOXY)PHENYL]ADAMANTANE; 2,2 BIS(4 AMINOPHENYL)ADAMANTANE; 2,2 BIS[4 (4 AMINO 3 HYDROXYPHENOXY)PHENYL]ADAMANTANE; 2,2 BIS[4 (4 AMINOPHENOXY)PHENYL]ADAMANTANE; ADAMANTANE DERIVATIVE; NSC 706832; NSC 706833; NSC 706834; NSC 706835; NSC 711117; NSC 711118; NSC 711119; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CENTRAL NERVOUS SYSTEM TUMOR; COLON ADENOCARCINOMA; COLON CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; EXAMINATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MALE; MOUSE; NONHUMAN; NUDE MOUSE; OBSERVATION; PRIORITY JOURNAL; SIDE EFFECT; SUBSTITUTION REACTION; XENOGRAFT;

ADAMANTANE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, INBRED ICR; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASM TRANSPLANTATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4143059114     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000136881.42423.98     Document Type: Article

References (22)

1. Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin N Am 2002; 31:925-943.
2. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. J Am Med Ass 1990; 19:1444-1448.
3. Hung DT, Jamison TF, Schreiber SL. Understanding and controlling the cell cycle with natural products. Chem Biol 1996; 3:623-639.
4. Sherr CJ. Cancer cell cycles. Science 1996; 274:1672-1677.
5. 1 phase progression: cycling on cue. Cell 1994; 79:551-555.
6. Aigami K, Inamoto Y, Takaishi N, Hattori K. Biologically active polycycloalkanes. 1. Antiviral adamantine derivatives. J Med Chem 1975; 18:713-721.
7. Tverdislov VA, el-Karadagi S, Kharitonenkov IG, Glaser R, Donath E, Herrmann A, et al. Interaction of the antivirus agents remantadine and amantadine with lipid membranes and the influence on the curvature of human red cells. Gen Physiol Biophys 1986; 5:61-75.
8. Chen HSV, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, et al. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 1992; 12:4427-4436.
9. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 1991; 206:297-300.
10. Donath E, Herrmann A, Coakley WT, Groth T, Egger M, Taeger M. The influence of the antiviral drugs amantadine and remantadine on erythrocyte and platelet membranes and its comparison with that of tetracaine. Biochem Pharmacol 1987; 36:481-487.
11. Tsuzuki N, Hama T, Kawada M, et al. Admantane as a brain-directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with the 1-admantane moiety. J Pharmac Sci 1994; 83:481-484.
12. Wang JJ, Chern YT, Chang YF, Liu TY, Chi CW. Dimethyladamantylmaleimide- induced in vitro and in vivo growth inhibition of human colon cancer Colo 205 cells. Anticancer Drugs 2002; 13:533-543.
13. Wang JJ, Chern YT, Liu TY, Chi CW. In vitro and in vivo growth inhibition of cancer cells by adamantylmaleimide derivatives. Anticancer Drug Des 1998; 13:79-96.
14. 1 arrest in human cancer cell lines by relatively low toxic diamantane derivatives. Anticancer Drugs 2004; 15:277-286.
15. Wang JJ, Chang YF, Chern YT, Chi CW. Study of the in vitro and in vivo effects of 1,6-Bis[4-(4-amino-3-hydroxyphenoxy)phenyl]diamantane (DPD), a novel cytostatic and differentiation inducing agent, on human colon cancer cells. Br J Cancer 2003; 89:1995-2003.
16. Yi MH, Huang W, Lee BJ, Choi KY. Synthesis and characterization of soluble polyimides from 2,2-bis(4-aminophenyl)cycloakane derivative. J Polym Sci Polym Chem 1999; 37:3449-3454.
17. Hsiao SH, Li CT. Synthesis and characterization of new adamantane-based polyimides. Macromolecules 1998; 31:7213-7217.
18. Chern YT, Shiue HC. Low dielectric constant polyimides derived from 1,3-bis(4-aminophenyl)adamantane. Macromol Chem Phys 1998; 199:963-969.
19. Chern YT, Shiue HC. Low dielectric constants of soluble polyimides based on adamantane. Macromolecules 1997; 30:4646-4651.
20. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 93:757-766.
21. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 1998; 77:1-10.
22. Gottardis MM, Jiang SY, Jeng MH, Jordan VC. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989; 49:4090-4093.